title: Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy.
abstract: It would be a clinical and economical advantage if the optimal time point of peripheral blood stem cell (PBSC) mobilization following G-CSF-supported chemotherapy (CT) was known in advance. Therefore, we retrospectively analyzed mobilization parameters in 113 adult tumor patients treated in our institution within 1 year. The start of apheresis was guided by CD34(+) cell measurements in the PB and occurred on or after day 11 after start of mobilization CT in 97% of patients. The median peak (p)CD34(+) cell count in PB uniformly occurred on day 14-15 (range: 6-32 days) after the start of CT, irrespective of the diagnosis (multiple myeloma n = 76, other histology n = 37), the type, but not the amount, of premobilization CT or radiotherapy (RT), the mobilization regimen, or the G-CSF dosage administered. Among more heavily pretreated patients (>six cycles of prior CT or RT), a higher proportion mobilized late (pCD34(+) cell count later than day 20 in 12% and 13%, respectively, versus 2%-5% in the other groups). Therefore, we propose to start measuring CD34(+) cells in the PB on day 11 after the start of mobilization therapy. The wide range of optimal mobilization time points argues for an individualized rather than a preset start of apheresis.
authors.affiliation: Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
authors.forename: Ruth
authors.initials: R
authors.lastname: Seggewiss
authors.forename: Eike Christian
authors.initials: EC
authors.lastname: Buss
authors.forename: Doris
authors.initials: D
authors.lastname: Herrmann
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: Anthony Dick
authors.initials: AD
authors.lastname: Ho
authors.forename: Stefan
authors.initials: S
authors.lastname: Fruehauf
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis / Q000096:biosynthesis; D001781:Blood Component Removal; D003131:Combined Modality Therapy; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012189:Retrospective Studies; D013234:Stem Cells / Q000737:chemistry / Q000166:cytology
chemical_list: D018952:Antigens, CD34; D016178:Granulocyte-Macrophage Colony-Stimulating Factor